NASDAQ:ARDS Aridis Pharmaceuticals - ARDS News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.71 -0.09 (-11.25%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.64▼$0.7850-Day Range$0.71▼$1.5052-Week Range$0.57▼$2.94Volume3.12 million shsAverage Volume2.13 million shsMarket Capitalization$14.77 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDS Media Mentions By Week ARDS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDS News Sentiment▼0.100.72▲Average Medical News Sentiment ARDS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDS Articles This Week▼80▲ARDS Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAnalysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)markets.businessinsider.com - January 27 at 8:30 AMHC Wainwright Cuts Aridis Pharmaceuticals (NASDAQ:ARDS) Price Target to $10.00americanbankingnews.com - January 27 at 8:12 AMAridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumoniamsn.com - January 26 at 9:52 AMAridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)finance.yahoo.com - January 25 at 6:34 PMNew Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Updatefinance.yahoo.com - January 17 at 7:06 PMAridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25finance.yahoo.com - December 28 at 1:24 PM(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundationfinance.yahoo.com - December 12 at 5:26 PMAridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundationfinance.yahoo.com - December 12 at 7:32 AMAridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceuticalfinance.yahoo.com - December 5 at 3:43 PMAridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patientsfinance.yahoo.com - November 30 at 8:32 AMAridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseasesfinance.yahoo.com - November 22 at 4:37 PMAridis Pharmaceuticals, Inc.: Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Updatefinanznachrichten.de - November 22 at 3:06 AMAridis Pharmaceuticals Late Monday Reported Q3 EPS $(0.47) Up From $(1.94) YoY, Sales $399.00K Down From $515.00K YoYbenzinga.com - November 22 at 3:06 AMAridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Updatefinance.yahoo.com - November 21 at 10:05 PMAridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimatesfinance.yahoo.com - November 21 at 10:05 PMDICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Studyfinance.yahoo.com - October 12 at 2:32 PMscPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approvalfinance.yahoo.com - October 11 at 11:02 PMAridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Studyfinance.yahoo.com - October 4 at 9:29 AMAridis Pharmaceuticals Announces Proposed Public Offering of Common Stockfinance.yahoo.com - September 26 at 7:21 PMWave Therapeutics (WVE) Up on Update From Huntington's Studyfinance.yahoo.com - September 21 at 3:29 PMARDS Aridis Pharmaceuticals, Inc.seekingalpha.com - September 20 at 11:03 PMbluebird's (BLUE) Gene Therapy Gets FDA Nod for CALDfinance.yahoo.com - September 19 at 2:18 PMIntellia (NTLA) Reports Positive Results for CRISPR Candidatesfinance.yahoo.com - September 19 at 2:18 PMAridis Pharmaceuticals, Inc. (ARDS)uk.finance.yahoo.com - September 16 at 12:38 AMAridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29Mseekingalpha.com - August 17 at 7:41 PMAridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimatesfinance.yahoo.com - August 16 at 11:39 PMAridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Updatefinance.yahoo.com - August 16 at 6:38 PMAridis' Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Actionfinance.yahoo.com - August 10 at 5:19 PMAridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primatesfinance.yahoo.com - August 10 at 12:18 PMHere's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishingnasdaq.com - July 1 at 4:49 PMRedChip Interviews Aridis Pharmaceuticals’ CEO Vu Truongapnews.com - July 1 at 11:48 AMRedChip Interviews Aridis Pharmaceuticals' CEO Vu Truongfinance.yahoo.com - June 30 at 10:31 AMAridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7finance.yahoo.com - June 3 at 10:03 AMAridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com - May 16 at 10:15 PMAridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Updatefinance.yahoo.com - May 16 at 5:14 PMAridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Studyfinance.yahoo.com - February 17 at 3:37 PMAridis stock rises 6% as antibody cocktail AR-701 protects against Omicron in animal modelsseekingalpha.com - February 17 at 10:36 AMWhy Aridis Pharma Is Rising In Pre-market?nasdaq.com - February 17 at 10:36 AMAridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animalsfinance.yahoo.com - February 17 at 10:36 AMWolfspeed, Galapagos, BlackBerry among premarket losers' packseekingalpha.com - January 31 at 9:19 AMHow Is The Market Feeling About Aridis Pharmaceuticals Inc?benzinga.com - January 28 at 1:57 PMPeering Into Aridis Pharmaceuticals Inc's Recent Short Interestmsn.com - January 27 at 5:56 PMAridis Shares Rise On Funding For Inhaled Monoclonal Antibodies Against Influenza, COVID-19finance.yahoo.com - January 27 at 12:51 PMLooking Into Aridis Pharmaceuticals Inc's Recent Short Interestmsn.com - January 27 at 12:51 PM(ARDS) - Analyzing Aridis Pharmaceuticals Inc's Short Interestmsn.com - January 27 at 12:51 PMAridis Gets $1.9 Mln Funding From Gates Foundation To Fight Influenza, Covid-19 In Poor Countriesmarkets.businessinsider.com - January 27 at 7:51 AMAridis wins funding from Gates Foundation to test inhalational COVID-19 antibodiesseekingalpha.com - January 27 at 7:51 AMAridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmissionfinance.yahoo.com - January 27 at 7:51 AMPre-market Movers: KPRX, CTK, VGR, BVXV, NEW…markets.businessinsider.com - December 30 at 7:44 AMH.C. Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktailfinance.yahoo.com - December 29 at 3:12 PM Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:ARDS) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.